Analyzing the tumor to predict cancer treatment response
Our diagnostics use AI to interpret solid tumors, so physicians and patients can make evidence-based decisions about cancer treatments
Our vision for more informed patients and physicians
Our mission is to remove the uncertainty from cancer treatment decisions, so physicians and patients don't have to make educated guesses about therapy selection
Our AI diagnostics deliver unparalleled insights into the tumor microenvironment and its downstream effects
Provide clear and actionable reports indicating the likelihood of therapeutic response
Patients and their loved ones can make more confident decisions based on unique evidence
Physicians are empowered to make informed treatment decisions, and improve the likelihood of success
Vesta is the only bladder cancer diagnostic that predicts treatment response to BCG using routine histology
Partnerships
Partnering with pharma to accelerate early research
We work with leading pharmaceutical companies, deploying our AI algorithms to advance R&D programs
Discovering biomarkers that predict response to therapies
Deploying diagnostics for biomarkers associated with therapy response
Automating screening for molecular biomarkers to increase enrollment, lower costs
ABOUT US
Valar Labs was founded to remove uncertainty from treatment decisions
Today, therapy selection is filled with uncertainty for oncologists and patients. Valar Labs exists to help them make more informed treatment decisions when it matters most.
Featured
Announcing Our $22 Million Series A to Accelerate AI in Precision Oncology
Co-led by DCVC and a16z, this funding will support the advancement of Vesta, world’s first AI test to predict treatment response in bladder cancer, and catalyze expansion in other cancers.